RADICAVA susp 105 mg/5ml buvable 2 fl 35 ml

7649998049023 CH-68016

No images available

Details

Product number
-
CPT
-
Packaging group
-
Unit
-

Official Swissmedic V2 data

Additional information from the official database

Official medical documents

Patient information leaflet
Allemand
18/03/2026
Patient information leaflet
Français
18/03/2026
Patient information leaflet
Italien
18/03/2026

Detailed composition

Substance Quantity Type Category
edaravonum
105.0 MG Substance Wirkstoff (Principe actif)
poly(alcohol vinylicus)
- Substance HNIDK
xanthani gummi
- Substance HNIDK
E 222
5.0 MG Substance HBESI
cysteini hydrochloridum monohydricum
- Substance HNIDK
natrii hydroxidum
- Substance HNIDK
acidum phosphoricum
- Substance HNIDK
sorbitolum
2000.0 MG Substance HBESI
simeticoni emulsio
- Substance HNIDK
aqua purificata
- Substance HNIDK
natrium
1.1 MG Substance HBESI

Authorization holder

Tanabe Pharma GmbH,

6300 Zug

Authorization information

Swissmedic authorization number
68016
Drug name
Radicava, Suspension zum Einnehmen
Galenic form
SUOR
ATC Code
N07XX14
Authorization status
Z
Dispensation category
B
First authorization
01/05/2023
Authorization expiration date
30/04/2028
IT number
01.99.0.
Domain
Human medicine
Field of application
Behandlung der amyotrophen Lateralsklerose (ALS)

Packaging details

Description (FR)
RADICAVA susp 105 mg/5ml buvable 2 fl 35 ml
Description (DE)
RADICAVA Susp 105 mg/5ml z Einnehmen 2 Fl 35 ml
Market launch
01/05/2023
Narcotic (BTM)
No

Other packaging sizes

RADICAVA susp 105 mg/5ml buvable fl 50 ml
50 ML
GTIN: 7649998049030
View
Buy us a coffee Explore the data